This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Hormone abuse in sports: the antidoping perspective
Osquel Barroso, Irene Mazzoni, Olivier Rabin
Science Department, World Anti-Doping Agency (WADA), Montreal, Quebec H4Z 1B7, Canada
Abstract
Since ancient times, unethical athletes have attempted to gain an unfair competitive advantage through the use of
doping substances. A list of doping substances and methods banned in sports is published yearly by the World
Anti-Doping Agency (WADA). A substance or method might be included in the List if it fulfills at least two of the following
criteria: enhances sports performance; represents a risk to the athlete's health; or violates the spirit of sports. This
list, constantly updated to reflect new developments in the pharmaceutical industry as well as doping trends,
enumerates the drug types and methods prohibited in and out of competition. Among the substances included are steroidal
and peptide hormones and their modulators, stimulants, glucocorticosteroids,
β2-agonists, diuretics and masking agents, narcotics, and cannabinoids. Blood doping, tampering, infusions, and gene doping are examples of prohibited
methods indicated on the List. From all these, hormones constitute by far the highest number of adverse analytical
findings reported by antidoping laboratories. Although to date most are due to anabolic steroids, the advent of
molecular biology techniques has made recombinant peptide hormones readily available. These substances are
gradually changing the landscape of doping trends. Peptide hormones like erythropoietin (EPO), human growth hormone
(hGH), insulin, and insulin-like growth factor I (IGF-I) are presumed to be widely abused for performance enhancement.
Furthermore, as there is a paucity of techniques suitable for their detection, peptide hormones are all the more
attractive to dishonest athletes. This article will overview the use of hormones as doping substances in sports,
focusing mainly on peptide hormones as they represent a pressing challenge to the current fight against doping.
Hormones and hormones modulators being developed by the pharmaceutical industry, which could emerge as new
doping substances, are also discussed.
(Asian J Androl 2008 May; 10: 391_402)
Keywords: World Anti-Doping Agency; doping; hormone; sport
Correspondence to: Dr Osquel Barroso, Science Department, World Anti-Doping Agency (WADA), Montreal, Quebec H4Z 1B7, Canada.
Tel: +1-514-904-8816 Fax: +1-514-904-4455
E-mail: osquel.barroso@wada-ama.org
Received 2007-11-28 Accepted 2007-12-01
DOI: 10.1111/j.1745-7262.2008.00402.x
1 Doping in sports and the World Anti-Doping Agency (WADA)
Doping is a problem that has plagued the world of competition and sport for ages. Even before the dawn of
Olympic history in ancient Greece, competitors have looked for artificial means to improve athletic performance
(from eating figs in ancient Greco-Roman times, to injecting with modern-era recombinant synthetic products). It
has taken several decades for sports organizations to realise the magnitude of the menace that doping poses to fair play
and the hazards it presents to the health and well-being of athletes, thereby triggering the recent establishment of the
systematic fight against doping.
It was only in 1967 that the International Olympic Committee (IOC) created a Medical Commission
that initiated the introduction of antidoping regulations, including the first official list of prohibited substances (listing exclusively
stimulants). The first doping control tests were carried out during the 1972 Munich Olympic Games, systematic
screening of urine samples was introduced at the 1983 Caracas Pan-American Games, and blood testing was first
implemented at the 1994 Lillehammer Winter Olympics.
WADA was created in 1999 as a result of the IOC-convened World Conference on Doping in Sport where both the
IOC and governments agreed to create an independent agency to promote, coordinate, and monitor the fight against
doping in sport internationally. The creation and implementation of the World Anti-Doping Code and the related
International Standards is one of WADA's main responsibilities. The Code constitutes the cornerstone for
harmonization of antidoping regulations across all sports and all countries.
2 Prohibited substances in sport
Doping is defined in the World Anti-Doping Code
(see the current version at
http://www.wada-ama.org/rtecontent/document/code_v3.pdf) as the occurrence of
an antidoping rule violation. Among the potential
violations of antidoping rules, those referring to the use or
attempted use of prohibited substances or methods
occupy a central place. Identifying prohibited
performance-enhancing substances used in sports is a growing global
challenge, one made more difficult by the development
of ever more sophisticated drugs and advanced methods
to avoid detection.
According to the Code, for a substance to be
considered for inclusion in the Prohibited List, it shall meet
two of the following three criteria: it has the potential to
enhance or enhances sport performance; it represents a
health risk for the athlete; or it is contrary to the spirit of
the sport. Importantly, the Code establishes the
principle of "strict liability", according to which the
presence of a prohibited substance (or its metabolites) in an
athlete's bodily specimen is enough to constitute an
antidoping rule violation, irrespective of the athlete's
personal culpability (intention or negligence) for such a
finding.
The performance-enhancing effects of any given substance are for the most part directly related to its
ergogenic effects (enhanced strength, higher energy
production, and better recovery), anabolic potential
(increased protein synthesis, especially in muscles),
and/or stimulating properties (increased attention and loss of
fear), which confer a competitive advantage to athletes.
The prohibited substances could be of two different
origins: exogenous, that is, not ordinarily capable of
being produced by the body naturally; or endogenous, that
is, substances naturally produced by the body.
Synthetic anabolic androgenic steroids (AAS), such as
methyltestosterone and nandrolone, are examples of the
former category. Endogenous hormones, such as human growth hormone (hGH), erythropoietin (EPO),
testosterone, dehydroepiandrosterone, and insulin, belong
to the latter group. Notwithstanding the potent effects
of many exogenous compounds, the endogenous and biosimilar agents (analogs of endogenous compounds
containing structural modifications that improve their
biological effects, e.g. insulin analogs) offer a clear
advantage to the dopers, in that they are more difficult to
detect. We will therefore concentrate on this group of
substances in this review.
2.1 Hormones as doping agents
2.1.1 AAS
AAS, a class of steroid hormones related to the male
hormone testosterone, are classic examples of doping
agents [1]. These compounds enhance athletic
performance by augmenting muscle mass and strength. AAS
are misused by athletes and non-athletes alike, including
schoolchildren, and there appears to be a trend for
giving potentially harmful high doses in combination with
other performance-enhancing drugs, such as hGH [2_6].
AAS are associated with serious adverse effects, such
as reduced fertility and gynecomastia in males,
masculinization in women, cardiovascular complications, cancer,
liver toxicity, behavioural disorders and, after chronic
high-dose usage, irreversible organ damage [6]. Still,
the strong and long-lasting benefits to performance
offered by these agents, their wide availability, and the
documented attempts to develop new generations of
sophisticated "designer" AAS that are increasingly difficult to
detect, make AAS an all too easy choice for athletes ready
to risk their health to get an unfair competitive advantage.
Recent high-profile investigations, conducted in the
USA, have shed light on the scale of this problem. The
notorious Bay Area Laboratory Cooperative case revealed
the extent of the involvement of elite athletes with a
laboratory devoted to the development of new classes of
anabolic steroids, such as tetrahydrogestrinone (THG)
and desoxymethyltestosterone (DMT). The "Operation
Which Doctor", recently conducted by the district
attorney's office in Albany (NY, USA), has exposed a
network created to distribute illegal AAS and other
doping substances. Furthermore, in 2005, federal
prosecutors successfully disrupted a network of Mexican
manufacturers supplying steroids to the US black market. A
few months ago, the US Drug Enforcement Agency, as
part of "Operation Raw Deal", seized more than 10
million doses of steroids and hGH from 56 laboratories in
the largest crackdown on illegal steroids in US history.
This investigation was assisted by the governments of
nine other countries, including China, which constitutes
a major source for the raw material.
AAS are among the most frequently detected drugs
in sport. Analytical methods based on the combination
of chromatographic (liquid chromatography [LC] or gas
chromatography [GC]) and mass-spectrometric (MS) as
well as isotope ratio MS (IRMS) approaches have been
developed and successfully implemented by WADA-accredited laboratories for the detection of many of these
compounds, including designer steroids (such as THG
and DMT). IRMS is particularly important for its ability
to discriminate between exogenous and endogenous AAS
like testosterone. Nevertheless, the results of these
investigations have illustrated the continued widespread use
of prohibited substances by athletes, in spite of the risks
of detection leading to an antidoping violation and tough
penalties that could lead to the end of their sporting career.
The combination of the development of more sophisticated detection methods and the increased
awareness of the antidoping authorities, led by WADA and
backed by the growing support of law-enforcement
agencies and the pharmaceutical industry, provides the basis
for the successful identification and banning of newly
developed performance-enhancing drugs, including
designer steroids.
2.1.2 Peptide hormones
Endogenous peptide hormones with potential
performance-enhancing properties are listed in WADA's List
of Prohibited Substances (see the 2008 List at
http://www.wada-ama.org/rtecontent/document/2008_List_En.pdf)
under section S2, "Hormones and related substances".
The following substances, and their releasing factors,
are prohibited: EPO; hGH; insulin-like growth factors
(IGF; e.g. IGF-I and mechano growth factors [MGF]);
gonadotrophins (e.g. luteinising hormone [LH] and
human chorionic gonadotrophin [hCG]); insulins; and
corticotrophins. Any other substance with similar
chemical structure or similar biological effect(s) also falls
under this section.
Recently, the misuse of endogenous hormones appears to have increased dramatically as a result of
several factors. First, the development of molecular biology
techniques, especially recombinant DNA technology, has
provided ample supplies of relatively cheap synthetic
hormones. With these synthetic versions, some of the
risks associated with the use of purified natural hormones,
such as the transmission of Creutzfeldt_Jacob disease
after using hGH isolated from cadaveric pituitary glands,
are eliminated [7]. Also, these substances are to a
significant degree structurally and biochemically identical
to the hormones naturally produced by the body, thereby
making their detection extremely challenging. They are
usually rapidly degraded and cleared from the body,
considerably narrowing the time window for their detection.
Some of them, such as hGH, are excreted in such minute
quantities in urine that urine analysis is not considered a
viable option. So far, the highly sophisticated
spectrometric methods used for detection of AAS have not been
successfully applied to these large and complex
biological proteins, despite recent advances in MS-based
testing of peptide hormones such as insulin, IGF-I, and hCG
[8_14]. In most cases, the current methodologies for
their detection rely on assays based on the
immunological recognition of each substance by specific antibodies,
which require individual development and extensive
validation.
2.1.2.1 Gonadotrophins
hCG is a glycoprotein of approximately 37 kDa that
belongs to a family of peptide hormones that also
includes follicle-stimulating hormone (FSH), LH, and
thyroid stimulating hormone [15, 16]. These are heterodimeric proteins made up of two polypeptide
chains, a common α subunit and an individual β subunit,
that determine the biological activity [16]. hCG, in
particular, has an extended highly glycosylated β-carboxy
terminus that facilitates its detection with specific
antibodies or through MS [12_14, 17, 18].
hCG is produced abundantly by the placental trophoblastic cells during pregnancy, stimulating steroid
hormone production in the ovaries [15]. Therefore, hCG
is used as a marker for pregnancy tests [19]. However,
due to its stimulation of endogenous steroid production,
leading to increased testosterone levels without affecting
the testosterone/epitestosterone ratio (used as a criteria
for detecting doping with exogenous testosterone), hCG
has also been used for doping purposes [20, 21]. Linked
to this action, the side-effects associated with hCG
misuse are similar to those induced by AAS. Although hCG
is not considered to be widely abused, its use can not be
ignored. Since its prohibition by the IOC back in 1987,
several male athletes have been found to have taken hCG.
LH is synthesized and secreted by gonadotropes in
the anterior lobe of the pituitary gland. LH mediates its
biological activity through the same receptor as hCG [15].
In females, the LH mid-cycle surge triggers ovulation
and induces the synthesis of progesterone and estrogens,
whereas in men it stimulates the production of
testosterone by Leydig cells [22, 23]. Human menopausal
gonadotrophin is a combination of FSH and LH that also has
the potential to be misused for performance-enhancing
purposes.
The presence of hCG and LH is currently
considered a doping violation if detected, above specific values,
in male athletes. In females, establishing the origin of
these peptide hormones (exogenous, or naturally produced) constitutes a challenging task. In particular,
hGH levels could remain high for several weeks
following early spontaneous miscarriage. In this regard,
urinary hCG testing in female athletes might expose an
unrecognized pregnancy, thus risking an invasion of
privacy. Furthermore, in contrast to men, hCG is
reported to have negligible effects on blood testosterone
levels in women [24].
Currently, hCG and LH are detected in urine doping
analysis by immunoassays using panels of
hormone-specific antibodies. However, some of these techniques
present inherent limitations [25]. Therefore, specific new
methods based on tandem mass spectrometry (MS/MS) and high-performance liquid chromatography combined
with MS/MS have been developed through WADA-sponsored research [12_14, 26].
2.1.2.2 hGH and IGF-I
hGH is a species-specific, single chain polypeptide
hormone expressed primarily in the somatotroph cells of
the pituitary gland. Its secretion into the circulation
follows a pulsatile pattern resulting in widely fluctuating
blood levels that are influenced by multiple factors such
as age, gender, sleep, physical activity, diet, stress, fever,
steroids, and the environment [27, 28].
In serum, hGH exists as a complex combination of
multiple isoforms including the major 22-kDa form (65%_80%) and minor isoforms resulting from
alternative mRNA splicing (20 kDa and 17.5 kDa) or proteolytic
cleavage of the mature protein (GH1_43 and
GH44_191) [29_31]. hGH also exists as dimers and oligomers of up to 5
units, linked through covalent and non-covalent bonds,
forming both homodimers and heterodimers [32].
Following secretion into the blood circulation, the unbound
22-kDa hGH has a short half-life of 10_20 min [27, 33,
34]. However, a proportion of circulating hGH forms
complexes with hGH binding proteins that protect hGH
from degradation and augment its half-life in circulation
[35].
At this time, hGH is believed to be one of the most
widely abused performance-enhancing agents. hGH is a
pleiotropic hormone that stimulates many metabolic
processes in cells. hGH affects protein, fat, carbohydrate,
and mineral metabolism [27, 36]. Historically, some of
the effects attributed to hGH, which might explain the
attraction for its use as a doping agent, include the
reduction of body fat and the increase in muscle mass (as
well as strength if combined with moderate exercise),
and its tissue-repairing effects on the musculoskeletal
system. However, the translation of these biological
effects into improvement in sports performance is based
on anecdotal evidence, as the current clinical evidence
of its anabolic effects in healthy adults is not well
documented.
Recombinant hGH (rhGH), when given to GH-deficient individuals, has been found to increase exercise
time and VO2max after 6 months of treatment [37, 38].
Increased body muscle mass, decreased body fat, increased cardiac output, and improved wound healing has
been described [28, 39]. In contrast, no significant
effects on muscle strength or muscle protein synthesis
have been reported in controlled clinical trials of healthy
non-exercising young men or athletes given
supraphysiological doses of rhGH [40, 41]. Similar
results have been reported in studies conducted with elderly men [42].
Despite the apparent lack of performance-enhancing effects in short-term studies with normal subjects,
rhGH is considered the doping drug of choice in a
number of endurance and power sports. The recovery of
great quantities of rhGH doses from "Operation Raw
Deal" and the links established between illegal
manufacturers and distributors and alleged high-profile athlete
recipients show that hGH is being misused and abused in
sports with the purpose of enhancing athletic performance.
Reportedly, it seems that athletes use hGH for long
periods of time with supratherapeutic doses or in
combination with other doping substances such as AAS. hGH
appears to act synergistically when used in tandem with
steroids, thus having an effect, albeit indirect, on muscle
anabolism and athletic performance [34, 43, 44].
IGF-I is a small 7.5-kDa peptide that has shown
anabolic effects on cytoskeletal muscles [45]. IGF-I
associates in plasma to high-affinity IGF-I binding proteins
(IGFBP), which increase its half-life in circulation.
Under normal conditions, 75%_80% of circulating IGF-I
remains bound to IGFBP-3 and the acid labile subunit
(ALS) in a ternary 150-kDa protein complex [46, 47].
Therefore, many factors that influence hGH
concentrations, such as circadian rhythm or the pulsatile nature of
pituitary hGH release, have minimal or no effect on IGF-I
[48].
hGH is one of the most important factors regulating
IGF-I synthesis and its release into circulation. Other
factors involved include nutrient intake, thyroid status,
and estrogen and cortisol levels [48]. The association
between hGH and IGF-I has been established by the low
IGF-I concentrations observed in hGH-deficient
pediatric patients and the elevated levels found in active
acromegaly [49]. In active adults, serum IGF-I levels
decline gradually with age, reflecting the concomitant drop
in hGH secretion [50].
Arguably, most of the growth and metabolic effects
of hGH are mediated by IGF-I, and include the increase
in total body protein turnover and muscle synthesis [51].
In any event, IGF-I is the most important marker of hGH
action in the liver [33]. hGH stimulates the liver to
produce IGF-I, which is secreted into circulation and acts,
in a paracrine manner, on other tissues of the body.
IGF-I has an anabolic effect, particularly in muscle, by
inducing protein synthesis through enhanced amino acid
uptake [51_53]. Experiments in mice injected with a
gene-delivery device that induces the myocyte overexpression
of IGF-I have shown an IGF-I-mediated increase in muscle mass (by 15%) and strength (by 14%), without
affecting IGF-I serum concentrations [54]. In addition,
IGF-I stimulates muscle glucose transport activity and
this effect is enhanced by acute bouts of intense exercise
and training [55].
Mechano growth factor (MGF or IGF-IEc) derives from an alternative splicing of the
IGF-I gene and is expressed in a mechano-sensitive manner in skeletal
muscles [56, 57]. The levels of MGF mRNA are low in
resting muscle, however, resistance exercise and local
tissue injury upregulate MGF expression, leading to the
activation of muscle satellite cells and initiation of muscle
hypertrophy [58, 59]. Due to these anabolic properties,
alleged MGF preparations are advertised and illegally sold
as anabolic agents over the Internet.
The long-term effects of rhGH on physical
performance and athletes' health are not known. As a result of
rhGH, levels of serum IGF-I are rapidly upregulated, and
they remain elevated for several days following rhGH
withdrawal [60]. The combination of hGH and exercise
has also been shown to markedly enhance the expression levels of MGF mRNA in muscle [58, 59]. Therefore,
the effects of this GH/IGF-I axis on muscle metabolism
would have an additive effect, probably seen in the
long-term after chronic hGH use.
hGH abuse by healthy persons could lead to serious
side-effects. Based on the pathological changes reported
in hGH-overproducing acromegalic patients, hGH abuse
might increase the risk of diabetes, hypertension,
cardiopathies, myopathy, osteoporosis, damage to joints
and articulations, abnormal bone growth, and disturbed
lipid patterns [28, 61].
The detection of doping with hGH constitutes a
significant challenge for antidoping authorities and antidoping
laboratories [34]. Despite the availability of multiple
assays that have been used to determine hGH for clinical
and research purposes, all are unsuitable to reliably
assess hGH abuse in sports [62_65]. Indeed, because hGH
is secreted in a pulsatile manner, an elevated
measurement may just reflect peak pituitary release of hGH. In
addition, exercise modifies the levels of hGH and the
release could be influenced by variations in nutritional intake,
stress, and other factors already mentioned, so it would
be difficult to rely on only a single blood analysis that
measures total hGH. To add to this complexity,
exogenous rhGH is structurally and biochemically
indistinguishable from the endogenous 22-kDa isoform, including
a very short half-life with hGH levels returning to normal
8_20 h after being given.
A novel approach to detect doping with rhGH, described as the isoform differential immunoassay, has been
proposed by Prof. Christian Strasburger and Drs Zida
Wu and Martin Bidlingmaier [66, 67]. The isoform
differential immunoassay was developed to detect hGH
doping by exploiting the differences in the proportions
of hGH isoforms under physiological conditions and
following doping practice. The method is based on the
essential principle that the normal composition of hGH in
blood is a mixture of different isoforms, present at
constant relative proportions. In contrast, rhGH is
constituted only of the 22-KDa molecular form. Exogenous
rhGH not only increases the concentration of the 22-KDa
isoform but also suppresses the non-22-kDa
concentrations for up to 4 days, thus altering the natural ratios
established between these hGH isoforms [68]. By using
two different immunoassays employing antibodies that
recognize the monomeric 22-kDa hGH or a combination
of pituitary-derived hGH isoforms, the elevated ratios of
22-kDa hGH to pituitary-derived hGH isoforms is used
to indicate doping with rhGH. The first versions of these
assays were implemented during the Olympic Games in
Athens 2004 and Turin 2006. Currently, a commercial
version of the assays, developed on a chemiluminescent
platform, has passed the stage of testing validation and is
due to be implemented across WADA-accredited laboratories.
This is the first step in tackling the abuse of hGH
with a newly developed detection method capable of
unequivocally identifying the use of exogenous rhGH.
However, the method has a critical limitation in that it
allows for detection in a short period of time, up to 36 h
after rhGH administration [67]. Consequently, its
effectiveness might be more suited for out-of-competition
testing, in which testing is carried out on an athlete at
any time without prior notice.
Other approaches are being developed in parallel to
these differential immunoassays. Due to its pleiotropic
nature, hGH affects the expression of many different
proteins that could serve as pharmacodynamic markers
of hGH activity. These include markers of hGH action
in the liver such as IGF-I, IGFBP-2, IGFBP-3, and ALS,
as well as markers of hGH action on bone formation and
resorption and on soft tissue collagen turnover,
including osteocalcin, N-terminal peptide of procollagen type
III (P-III-P), C-terminal telopeptide of type I collagen,
and C-terminal propeptide of type I collagen
[34, 69]. The detection of such markers would uncover the
manipulation of the hGH/IGF-I axis independently of the
doping substance used, be it rhGH or other agents used
to increase circulating hGH (e.g. analogs of
GH-releasing hormone, hGH secretagogs, or even hGH gene
doping). In studies conducted as part of the GH-2000
and GH-2004 projects [60], two particular markers,
IGF-I and P-III-P, have been found to be particularly
sensitive to the effects of exogenous hGH [70, 71]. Whereas
the concentrations of circulating IGF-I rise rapidly after
hGH use, the levels of P-III-P increase more gradually
and stay upregulated for a longer period of time.
Discriminatory formulae based on measured blood
concentrations of these two proteins have been developed,
allowing for optimal identification of rhGH administration
samples for longer detection periods [70, 71]. The final
aim is to combine both approaches, the differential
isoform immunoassay and the marker detection, to
increase the chances of detecting doping with hGH both in
and out of competition.
2.1.2.3 EPO
EPO is a 30.4-kDa glycoprotein hormone that is mainly
produced by the kidney and is a key regulator of red
blood cell production [72_74]. EPO stimulates the
proliferation and differentiation of bone marrow erythroid
precursors [75].
The introduction of recombinant EPO (rhEPO) has
permitted the effective therapeutic treatment of anaemia
associated with chronic kidney disease, HIV,
myelodysplastic syndromes, bone marrow transplantation,
hepatitis C, or following chemotherapy regimes against cancer
[75_78]. First-generation rhEPO products include
epoietin-α and -β, produced in transformed Chinese
hamster ovary (CHO) cell cultures, and epoietin-ω, engineered
in baby hamster kidney (BHK) cells [79].
EPO in blood circulation consists of isoforms that
differ in their patterns of glycosylation and biological
activity [80, 81]. The carbohydrate moiety of EPO
consists of one O-linked and three N-linked sugar residues
[82]. The sialic acid-ending N-glycans are essential for
EPO's biological functions and duration in circulation
[83]. A novel recombinant EPO (epoietin-δ or Dynepo)
is produced in a human fibrosarcoma cell line (HT-1080),
thus having a more human-like glycosylation pattern
characterized by the absence of N-glycolylneuraminic acid
[84]. The presence of extra N-glycans increases the
half-life, and therefore the duration of biological effects,
in vivo, of some recombinant EPO products such as
darbepoietin-α (Aranesp, derived in CHO cells) [85, 86].
In contrast, de-sialylated EPO is rapidly removed from
circulation. This apparent advantage of longer duration
offered by the modified rhEPO might serve, conversely,
to facilitate its detection by antidoping laboratories.
The recent expiration of patents protecting the
intellectual property and marketing rights of the
first-generation rhEPOs has further increased the menace of EPO
abuse in sports due to the emergence of so-called "biosimilars" and generic copies of established EPO
products [87]. Several other EPO analogs and derived
molecules are also in different stages of pharmaceutical
development, including continuous erythropoiesis
receptor activator, a recently commercialized pegylated
epoietin-α, a hyperglycosylated darbepoietin-α analog (AMG
114), the polymer-bound analog synthetic erythropoiesis
protein (SEP), and EPO molecules fused to the Fc
region of a human antibody or to another EPO molecule
through flexible chemical linkers [88]. All of these
preparations have been designed to increase the half-life in
circulation and extend the biological effects of EPO
in vivo. EPO mimetics (compounds structurally unrelated
to EPO but with similar biological activity due to their
ability to engage the EPO receptor) and hypoxia inducible
factor-1 (HIF-1) agonists constitute additional efforts to
mimic the actions of EPO in a clinical situation [87].
Due to its effect of increasing hemoglobin
(Hgb)-bearing erythrocytes responsible for the
oxygen-carrying capacity of the blood, EPO has been used
extensively as a performance-enhancing aid in sports,
particularly in endurance disciplines requiring an adequate
supply of oxygen to the heart and the muscles. The first
suspected cases of blood doping with recombinant EPO
date back to the late 1980s, when a cluster of sudden
deaths of European cyclists was associated with its
market appearance [88]. Since then, numerous examples of
doping with EPO have made the headlines. Most notoriously, the affair involving the Festina team during
the 1998 Tour de France revealed a widespread abuse of
EPO in cycling and led to a drastic change in the IOC's
approach to doping in sports and ultimately to the
creation of WADA. The withdrawal of six Chinese female
track and field athletes from the Sydney 2000 Olympics
coincided with the introduction of the first EPO blood
tests, fuelling suspicions of EPO abuse as the cause for
their previous exceptional performances. During the Salt
Lake City 2002 Winter Olympics four athletes were stripped of their medals after being found positive for
darbepoietin-α. The "Operación Puerto" investigation
of a medical clinic in Spain, linking several elite cyclists
with blood-doping methods, uncovered multiple doses
of EPO and bags of frozen blood for reinfusion. Recently,
a Canadian cyclist, Genevieve Jeanson, has admitted to
having used EPO throughout her career after many years
of denial. Many other examples of EPO abuse by elite
athletes have been and are still being reported.
The excessive use of EPO is associated with serious
adverse side-effects, including hypertension, headaches,
and an increased rate of thrombotic events as a result of
an EPO-induced rise in the hematocrit and thickening of
the blood [89, 90]. In addition, EPO withdrawal could
be implicated in neocytolysis, that is, the hemolysis of
young red blood cells in the presence of increased
hematocrit [91]. Ultimately, EPO abuse could cause death.
Methods for detection of doping with EPO include
the combination of direct and indirect approaches [75].
The direct method currently used in WADA-accredited
antidoping laboratories is based on differences in the
pattern and extent of glycosylation of rhEPO as compared
to the endogenously produced protein. The glycosylation
pattern of rhEPO preparations is determined by several
factors, including the cell line from which they are
recombinantly expressed, the media employed for cell
culturing, and the methods of protein purification [87].
The different arrangements of sugar residues found in
rhEPOs result in differences in their isoelectric points
that are detected by a method combining isoelectric
focusing (IEF) and double immunoblotting [92_94]. The
situation is more complicated for the detection of EPO
variants produced in human cells, such as darbepoietin.
Nevertheless, it is unlikely that darbepoietin behaves
exactly as endogenous EPO using IEF, because the pattern
of bound N-glycans is also tissue-specific [87].
The indirect methods incorporate changes of
hematological parameters of erythropoiesis, such as Hgb,
percentage of reticulocytes, and serum concentrations of
EPO and soluble transferring receptors [75]. Some of
these parameters could be disturbed for up to 4 weeks
after rhEPO use, thereby increasing the chances of
detection. In addition, such methods might offer the
advantage of detecting other manipulations aside from
the use of rhEPO. Algorithms have been developed that
are capable of detecting the use of rhEPO either during
the administration phase (ON-model: Hgb, EPO, and soluble transferring receptors) or during the wash-out
period (OFF-model: Hgb and reticulocytes) [95]. The
former model detects up to 100% of rhEPO-containing
samples during the period of use, but has a short time
window of detection (approximately 48 h) following
injection of relatively low doses of EPO. In contrast, the
OFF-model allows detection for up to 2 weeks after EPO
withdrawal [96_98].
During the Sydney 2000 Olympics, a combination of the direct and indirect blood methods for detection of
EPO was implemented. However, since 2004, only the
urine-based IEF method has been used for the direct
analysis of EPO use. Nevertheless, the indirect EPO
methods will be integrated in the model foreseen for the
creation of the hematological module of the athlete's
passport (longitudinal follow-up over time of the athlete's
biological parameters).
Currently, WADA is sponsoring several research projects aimed at improving the efficacy of this method
as well as finding alternative approaches, such as the
assay currently in development by the Swedish
biotechnology company MAIIA (Uppsala, Sweden). Likewise,
WADA has funded the development of a potent software
tool, GasEPO, a support for the interpretation of IEF
results [99].
An alternative indirect approach is the athlete's
hematological passport, that is, the establishment of
individual hematological profiles by the comparison of
measured values of blood parameters against the individual's
historical baseline, considered an effective tool for
doping control. This approach would eliminate the
inter-individual variability observed in the population-derived
ranges currently used. Deviations from the normal
longitudinal profile would result in a ban from participating
in a particular competition, and in further investigations
to establish an incidence of doping or possibly sanction
for an antidoping rule violation. Recently, the Union
Cycliste Internationale (UCI) became the first
international sports federation to implement the athlete's
hematological passport approach as part of its antidoping
program. The application of longitudinal profiling might
also help to eliminate reported cases of undetectable EPO
profiles that have been observed in various situations and
might have been caused by manipulation of the sample
with EPO-degrading proteases [100].
2.1.2.4 Insulins
Insulin is produced by β cells in pancreatic islets
through a complex proteolytic process involving the
enzymatic cleavage of pro-insulin (9.6-kDa) into insulin and
C-peptide. Human insulin is a 5.8-kDa polypeptide
hormone consisting of two peptide chains of 21 (A) and 30
(B) amino acid residues connected by disulfide
bonds. Insulin molecules are capable of self-association into
hexameric aggregates, but only the monomers have
biological activity [101].
Insulin is primarily used to treat insulin-deficient
patients suffering from type 1 diabetes mellitus. However,
due to its influence on many metabolic processes,
insulin is also a potential performance-enhancing agent [51].
Insulin increases the rate of glucose uptake into adipose
and muscle tissues and stimulates glycogenesis, thus
increasing the intramuscular energy reserves. The
combination of short-acting insulin and high carbohydrate
diets has an anabolic effect on muscle mass through the
inhibition of protein breakdown. The use of insulin could
also improve post-competition recovery and stamina [33].
In addition to the availability of recombinant human
insulins, such as neutral protamine hagedorn (NPH),
several other insulin analogs have been developed, with
altered pharmacokinetics compared with the naturally
produced insulin. These compounds, produced by
recombinant DNA technology, are classified into rapid-acting
(e.g. aspart [NovoLog] and lispro [Humalog]) and
long-acting (e.g. glargine [Lantus]) synthetic insulins that
differ from human insulin only slightly in amino acid
sequences [102_104].
The detection of insulin in biological fluids
represents a complicated task. In blood, hemolysis and/or the
presence of circulating anti-insulin antibodies can
interfere with the results of the analyses. In urine, insulin is
mainly excreted as a product of its metabolic degradation.
Therefore, physiological urine concentration levels of
native insulin are in the fentomolar range, requiring
extremely sensitive assays for its detection. The detection
of insulin in urine has, until recently, been done with the
use of commercially available radioimmunoassays or
enzyme-linked immunosorbent assays. Many of these
assays, however, show cross-reactivity with human
pro-insulin or products of degradation and are not
discriminant enough to differentiate insulin from its synthetic
analogs. A sensitive radioimmunoassay test has been
developed for the detection of insulin lispro and an
enzyme-linked immunosorbent assay test, specific for insulin
aspart, has also been reported [105, 106]. Recently, a
new analytical method involving the combination of a
sophisticated sample preparation procedure and LC-MS
has been developed, with financial support from WADA,
for the identification of endogenous and synthetic insulins
in urine [8, 9].
2.1.2.5 Other hormone-related doping agents
One of the side-effects of using AAS includes the
excessive production of estrogens that results in the
development of gynecomastia and the suppression of
endogenous testosterone [107]. In order to overcome these
negative effects, athletes abusing AAS use anti-estrogenic
drugs. In addition, a number of anti-estrogens increases
testosterone blood concentrations in normal men through
a rise in the pituitary release of LH [24]. Three main
categories of anti-estrogens can be distinguished:
1. Selective estrogen receptor modulators
(SERMs). These compounds, used for the treatment of breast cancer
and osteoporosis, can act as agonists or antagonists of the
estrogen receptor, depending on the cell type and tissue.
For example, SERMs like tamoxifen and raloxifen are
estrogen antagonists in breast tissue, but they act as estrogen
agonists in bone [108, 109].
2. Aromatase inhibitors (AIs). These compounds
block the synthesis of estrogen by inhibiting the activity
of estrogen synthetase. They have also been developed
for the treatment of postmenopausal breast cancer. Two
types of AIs have been produced: type I inhibitors (e.g.
4-hydroxyandrostenedione), steroidal substrate analogs
that inactivate the enzyme; and type II inhibitors (e.g.
letrozole, anastrozole) that are non-steroidal competitive
reversible inhibitors [110].
3. Other anti-estrogenic substances. These include
estrogen receptor antagonists with no agonist effect, such
as fulvestrant, prescribed for treatment of breast cancer,
as well as clomiphene, used to treat infertility [111, 112].
For doping control purposes, anti-estrogens are
detected by classical analytical chromatographic methods
like LC-MS (e.g. exemestane, formestane, tamoxifen, and
toremifene) [113_116] and GC-MS (e.g. aminoglutethimide)
[117]. WADA has sponsored research projects to develop methods to detect anastrozole (by LC-MS/MS) and
letrozole (by GC-MS) [113, 118] and is currently
funding projects to synthesize certified reference materials
for some of these anti-estrogenic compounds and their
metabolites.
2.1.2.6 Hormones and hormone modulators in
development
In addition to classical steroid and peptidic hormones,
new classes of hormone agonists, antagonists, and
modulators are constantly being developed by the
pharmaceutical industry. WADA regularly monitors the clinical stages
of investigational drugs as some of these could be used
for sports performance enhancement. Once identified,
projects aimed at detecting these new drugs before they
are released into the market are funded by the Agency.
Some examples are listed below.
2.1.2.6.1 Selective androgen receptor modulators
(SARMs)
AAS are clinically prescribed to treat medical
conditions such as male hypogonadism, muscle wasting
disease, osteoporosis, and sarcopenia. However, due to
their negative effects on high-density lipoprotein
cholesterol levels and cardiovascular and prostate systems, other
therapeutic alternatives are being sought. Recently, a
novel class of investigational drugs, the SARMs, have
been developed and some, like Ostarine (GTx, Memphis,
TN, USA), are already undergoing phase II/III
clinical trials [119]. These drugs appear to have the advantage of
acting as full agonists of the androgen steroid receptor in
target tissues such as muscle and bone, but they have
minimal affect on organs such as the prostate and do not
induce virilization [119].
As AAS are widely abused as doping substances, it
is expected that SARMs, which retain all the advantages
of enhancing performance while avoiding undesirable
side-effects, will also be sought as doping substances.
In anticipation of this trend, WADA is currently funding
research projects to detect the misuse of SARMs.
2.1.2.6.2 Inhibitors of myostatin
Myostatin, also known as growth and differentiation
factor 8, is a secreted protein and member of the
transforming growth factor-β family that plays an essential
role in skeletal muscle growth [120, 121]. Myostatin
negatively modulates muscle satellite cell proliferation and
inhibits muscle cell differentiation. Follistatin can
interact with myostatin C-terminus, precluding its binding to
the activin receptors and thus negatively modulating
myostatin function [122]. Due to its properties, the
naturally occurring mutations related to loss of function in
the highly conserved myostatin gene produce muscle
hypertrophy in both humans and animals [123, 124]. Mice
carrying a targeted disruption of the myostatin gene show
muscle fiber hypertrophy, hyperplasia, and a partial
suppression of abnormal glucose metabolism and fat
accumulation [125, 126]. Transgenic mice expressing a
dominant negative activin II receptor or overexpressing follistatin
also have dramatic increases in muscle mass [127].
In consideration of these properties, myostatin
inhibitors have become attractive development drugs for
the pharmaceutical industry. It is foreseen that such
compounds will be used as therapeutic treatments for
muscle wasting diseases such as sarcopenia associated
with aging, cancer cachexia, AIDS, amyotropic lateral
sclerosis, and muscular dystrophy. Several myostatin
inhibitors are under clinical development and their
effects are based on the reduction of bioavailable myostatin.
These include antibodies or fusion proteins directed
against myostatin as well as soluble activin type II
receptors [128_130].
Myostatin inhibitors have the potential to be a
tempting doping option for cheating athletes. Although these
compounds are still under clinical development, and in
theory years away from commercialization, WADA has
taken a proactive approach to include them on the
Prohibited List and is currently funding research projects
aimed at the detection of doping with myostatin inhibitors.
3 Conclusions
The sports world has made significant steps in the
last few years to fight off the stigma of doping. However,
it is envisaged that new doping threats will quickly emerge
on the horizon. Therefore, the antidoping community,
led by WADA and with the essential support of scientists
and organizations committed to antidoping, will have to
intensify current efforts. The wide availability of
recombinant products similar to endogenous hormones,
the generation of biosimilars and biological generics,
analogs, and releasing factors of currently detectable
substances, the potential threat of gene doping, and the
appearance of new designer drugs, to name a few, can all
lead to new doping practices against which appropriate
doping control and detection methods must be developed.
Complimentary to an effective testing program, a strong
educational component is also needed to educate elite
and occasional athletes on the serious health risks related
to doping. A close cooperation between antidoping
organizations and law-enforcing agencies for the
identification and tackling of illegal drug manufacturers and
supply chains also constitutes an essential element
towards the success of the fight against doping in sports.
Acknowledgment
The authors appreciate the comments and suggestions of Mr Thierry Boghosian, WADA's Laboratory
Accreditation Manager, and Mrs Victoria Ivanova, WADA's
Scientific Projects Manager, in the writing of this review
article.
References
1 Handelsman DJ. Testosterone: use, misuse and abuse. Med J Aust
2006; 185: 436_9.
2 Parkinson AB, Evans NA. Anabolic androgenic steroids: a
survey of 500 users. Med Sci Sports Exerc 2006; 38: 644_51.
3 Thiblin I, Petersson A. Pharmacoepidemiology of anabolic
androgenic steroids: a review. Fundam Clin Pharmacol 2004; 19:
27_44.
4 Handelsman DJ, Gupta L. Prevalence and risk factors for
anabolic-androgenic steroid abuse in Australian high school students.
Int J Androl 1997; 20: 159_64.
5 Barrientos-Pérez M. Uso de anabolicos por atletas adolescentes.
Rev Endocrinol Nutr 2001; 9: 133_40.
6 Sánchez-Osorio M, Duarte-Rojo A, Martínez-Benítez B, Torre
A, Uribe M. Anabolic_androgenic steroids and liver injury. Liver
Int 2008; 28: 278_82.
7 Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia, and
Creutzfeldt-Jakob disease in patients treated with human
pituitary growth hormone in the United Kingdom. BMJ 1991; 302:
824_8.
8 Thevis M, Thomas A, Delahaut P, Bosseloir A, Schänzer W.
Doping control analysis of intact rapid-acting insulin analogues
in human urine by liquid chromatography-tandem mass
spectrometry. Anal Chem 2006; 78: 1897_903.
9 Thomas A, Thevis M, Delahaut P, Bosseloir A, Schänzer W.
Mass spectrometric identification of degradation products of
insulin and its long-acting analogues in human urine for doping
control purposes. Anal Chem 2007; 79: 2518_24.
10 Nelson RW, Nedelkov D, Tubbs KA, Kiernan UA. Quantitative
mass spectrometric immunoassay of insulin-like growth
factor-1. J Proteome Res 2004; 3: 851_5.
11 Bobin S, Popot MA, Bonnaire Y, Tabet JC. Approach to the
determination of insulin-like growth factor-I (IGF-I)
concentration in plasma by high-performance liquid chromatography_ion
trap mass spectrometry: use of a deconvolution algorithm for
the quantification of multiprotonated molecules in electrospray
ionization. Analyst 2001; 126: 1996_2001.
12 Gam LH, Tham SY, Latiff A. Immunoaffinity extraction and
tandem mass spectrometric analysis of human chorionic
gonadotropin in doping analysis. J Chromatogr B Analyt Technol
Biomed Life Sci 2003; 792: 187_96.
13 Liu C, Bowers LD. Mass spectrometric characterization of the
α-subunit of human chorionic gonadotropin. J Mass Spectrom
1997; 32: 33_42.
14 Liu C, Bowers LD. Immunoaffinity trapping of urinary human
chorionic gonadotropin and its high-performance liquid
chromatographic_mass spectrometric confirmation. J Chromatogr
B Biomed Appl 1996; 687: 213_20.
15 Stenman UH, Alfthan H, Hotakainen K. Human chorionic
gonadotropin in cancer. Clin Biochem 2004; 37: 549_61.
16 Pierce JG, Parsons TF. Glycoprotein hormones: structure and
function. Annu Rev Biochem 1981; 50: 465_95.
17 Birken S, Berger P, Bidart JM, Weber M, Bristow A, Norman R,
et al. Preparation and characterization of new WHO reference
reagents for human chorionic gonadotropin and metabolites.
Clin Chem 2003; 49: 144_54.
18 Birken S, Canfield R, Agosto G, Lewis J. Preparation and
characterization of an improved β-COOH-terminal immunogen for
generation of specific and sensitive antisera to human chorionic
gonadotropin. Endocrinology 1982; 110: 1555_63.
19 Butler SA, Khanlian SA, Cole LA. Detection of early pregnancy
forms of human chorionic gonadotropin by home pregnancy
test devices. Clin Chem 2001; 47: 2131_6.
20 de Boer D, de Jong EG, van Rossum JM, Maes RA. Doping
control of testosterone and human chorionic gonadotrophin: a
case study. Int J Sports Med 1991; 12: 46_51.
21 Johnson MR, Carter G, Grint C, Lightman SL. Relationship
between ovarian steroids, gonadotrophins and relaxin during the
menstrual cycle. Acta Endocrinol (Copenh) 1993; 129: 121_5.
22 Robinson N, Saudan C, Sottas PE, Mangin P, Saugy M.
Performance characteristics of two immunoassays for the
measurement of urinary luteinizing hormone. J Pharm Biomed Anal
2007; 43: 270_6.
23 Wunsch A, Sonntag B, Simoni M. Polymorphism of the FSH
receptor and ovarian response to FSH. Ann Endocrinol (Paris)
2007; 68: 160_6.
24 Handelsman DJ. Clinical review: the rationale for banning
human chorionic gonadotropin and estrogen blockers in sport. J
Clin Endocrinol Metab 2006; 91: 1646_53.
25 Leinonen A, Tahtela R, Karjalainen E. Detection of human
chorionic gonadotrophin in urine by two different immunoassays. In:
Schanzer W, Geyer H, Gotzmann A, Mareck-Engelke U, editors.
Proceedings of the 16th Cologne Workshop on Doping Analysis.
15_20 March 1998, Cologne, Germany. Cologne: Sport and Buch
Strauss; 1999.
26 Bowers LD. Analytical advances in detection of
performance-enhancing compounds. Clin Chem 1997; 43: 1299_304.
27 Daughaday W, Parker ML. Human pituitary growth hormone.
Ann Rev Med 1965; 16: 47_66.
28 Ehrnborg C, Bengtsson BA, Rosen T. Growth hormone abuse.
Baillieres Best Pract Res Clin Endocrinol Metab 2000; 14: 71_7.
29 Lewis UJ, Dunn JT, Bonewald LF, Seavey BK, Vanderlaan WP. A
naturally occurring structural variant of human growth hormone.
J Biol Chem 1978; 253: 2679_87.
30 DeNoto FM, Moore DD, Goodman HM. Human growth
hormone DNA sequence and mRNA structure: possible alternative
splicing. Nucleic Acids Res 1981; 9: 3719_30.
31 Lecomte CM, Renard A, Martial JA. A new natural hGH variant
-17.5 kd-produced by alternative splicing. An additional
consensus sequence which might play a role in branchpoint selection.
Nucleic Acids Res 1987; 15: 6331_48.
32 Stolar MW, Amburn K, Baumann G. Plasma "big" and "big-big"
growth hormone (GH) in man: an oligomeric series composed of
structurally diverse GH monomers. J Clin Endocrinol Metab
1984; 59: 212_8.
33 Sonksen PH. Insulin, growth hormone and sport. J
Endocrinol 2001; 170: 13_25.
34 McHugh CM, Park RT, Sonksen PH, Holt RI. Challenges in
detecting the abuse of growth hormone in sports. Clin Chem
2005; 51: 1587_93.
35 Baumann G, Amburn KD, Buchanan TA. The effect of
circulating growth hormone-binding protein on metabolic clearance,
distribution, and degradation of human growth hormone. J Clin
Endocrinol Metab 1987; 64: 657_60.
36 Chawla RK, Parks JS, Rudman D. Structural variants of human
growth hormone: biochemical, genetics and clinical aspects. Ann
Rev Med 1983; 34: 519_47.
37 Cuneo RC, Salomon F, Wiles CM, Hesp R, Sonksen PH. Growth
hormone treatment in growth-hormone deficient adults. I.
Effects on muscle mass and strength. J Appl Physiol 1991; 70:
688_94.
38 Beshyah SA, Shahi M, Foale R, Johnston DG. Cardiovascular
effects of prolonged growth hormone replacement in adults. J
Intern Med 1995; 237: 35_42.
39 Salomon F, Cuneo R, Hesp R, Sonksen P. The effects of
treatment with recombinant human growth hormone on body
composition and metabolism in adults with growth hormone
deficiency. N Engl J Med 18989; 321: 1797_803.
40 Deyssig R, Frisch H, Blum WF, Waldhör T. Effect of growth
hormone treatment on hormonal parameters, body composition
and strength in athletes. Acta Endocrinol 1993; 128: 313_8.
41 Yarasheski KE, Campbell JA, Smith K, Rennie MJ, Holloszy JO,
Bier DM. Effect of growth hormone and resistance exercise on
muscle growth in young men. Am J Physiol 1992; 262: E261_7.
42 Taaffe DR, Jin IH, Vu TH, Hoffman AR, Marcus R. Lack of
effect of recombinant human growth hormone (GH) on muscle
morphology and GH-insulin-like growth factor expression in
resistance-trained elderly men. J Clin Endocrinol Metab 1996;
81: 421_5.
43 Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks
JB, et al. Single and combined effects of growth hormone and
testosterone administration on measures of body composition,
physical performance, mood, sexual function, bone turnover,
and muscle gene expression in healthy older men. J Clin
Endocrinol Metab 2002; 87: 5649_57.
44 Garvan Institute press release. Available from:
http://www.garvan.org.au/news-events/news-archive/2007/media_release.2007-06-
27.2213613206/?searchterm=dr
45 Rinderknecht E, Humbel RE. The amino acid sequence of human
insulin-like growth factor-I and its structural homology with
proinsulin. J Biol Chem 1978; 253: 2769_76.
46 Jones JI, Clemmons DR. Insulin-like growth factors and their
binding proteins: biological actions. Endocr Rev 1995; 16:
3_34.
47 Ranke MB, Elmlinger M. Functional role of insulin-like growth
factor binding proteins. Horm Res 1997; 48: 9_15.
48 De Palo EF, Gatti R, Lancerin F, Cappellin E, Spinella P.
Correlations of growth hormone (GH) and insulin-like growth factor I
(IGF-I): effects of exercise and abuse by athletes. Clin Chim Acta
2001; 305: 1_17.
49 Furlanetto RW, Underwood LE, Van Wyk JJ, D'Ercole AJ.
Estimation of somatomedin-C levels in normals and patients with
pituitary disease by radioimmunoassay. J Clin Invest 1977; 60:
648_57.
50 Rudman D, Kutner MH, Rogers CM, Lubin MF, Fleming GA,
Bain RP. Impaired growth hormone secretion in the adult
population: relation to age and adiposity. J Clin Invest 1981; 67:
1361_9.
51 Fryburg DA, Jahn LA, Hill SA, Oliveras DM, Barrett EJ. Insulin
and insulin-like growth factor I enhance human skeletal muscle
protein anabolism during hyperaminoacidemia by different
mechanisms. J Clin Invest 1995; 96: 1722_9.
52 Fryburg DA, Gelfand RA, Barrett EJ. GH acutely stimulates
forearm muscle protein synthesis in normal humans. Am J
Physiol 1991; 260: E499_504.
53 Healy ML, Gibney J, Russell-Jones DL, Pentecost C, Croos P,
Sonsksen PH, et al. High-dose GH exerts an anabolic effect at
rest and during exercise in endurance-trained athletes. J Clin
Endocrinol Metab 2003; 88: 5221_6.
54 Barton-Davis ER, Shoturma DI, Musaro A, Rosenthal N, Sweeney
HL. Viral mediated expression of insulin-like growth factor I
blocks the aging-related loss of skeletal muscle function. Proc
Natl Acad Sci USA 1998; 95: 15603_7.
55 Hokama JY, Streeper RS, Henriksen EJ. Voluntary exercise
training enhances glucose transport in muscle stimulated by
insulin-like growth factor I. J Appl Physiol 1997; 82: 508_12.
56 Yang S, Alnaqeeb M, Simpson H, Goldspink G. Cloning and
characterization of an IGF-I isoform expressed in skeletal muscle
subjected to stretch. J Muscle Res Motil 1996; 17: 487_95.
57 McKoy G, Ashley W, Mander J, Yang SY, Williams N, Russell B,
et al. Expression of insulin growth factor-1 splice variants and
structural genes in rabbit skeletal muscle induced by stretch and
stimulation. J Physiol 1999; 526: 583_92.
58 Hameed M, Orrell RW, Cobbold M, Goldspink G, Harridge SD.
Expression of IGF-I splice variants in young and old human
skeletal muscle after high resistance exercise. J Physiol 2003;
547: 247_54.
59 Hameed M, Lange KH, Andersen JL, Schjerling P, Kjaer M,
Harridge SD, et al. The effect of recombinant human growth
hormone and resistance training on IGF-I mRNA expression in
the muscles of elderly men. J Physiol 2003; 555: 231_40.
60 Erotokritou-Mulligan I, Bassett EE, Kniess A, Sonksen P, Holt
RI. Validation of the growth hormone (GH)-dependent marker
method of detecting GH abuse in sport through the use of
independent data sets. Growth Horm IGF Res 2007; 17: 416_23.
61 McNab TL, Khandwala HM. Acromegaly as an endocrine form
of myopathy: case report and review of literature. Endocr Pract
2005; 11: 18_22.
62 Tsushima T, Katoh Y, Miyachi Y, Chihara K, Teramoto A, Irie
M, et al. Serum concentration of 20K human growth hormone
(20K hGH) measured by a specific enzyme-linked immunosorbent
assay. Study Group of 20K hGH. J Clin Endocrinol Metab 1999;
84: 317_22.
63 Tanaka T, Shiu RP, Gout PW, Beer CT, Noble RL, Friesen
HG. A new sensitive and specific bioassay for lactogenic hormones:
measurement of prolactin and growth hormone in human serum.
J Clin Endocrinol Metab 1980; 51: 1058_63.
64 Hashimoto Y, Ikeda I, Ikeda M, Takahashi Y, Hosaka M, Uchida
H, et al. Construction of a specific and sensitive sandwich
enzyme immunoassay for 20 kDa human growth hormone. J
Immunol Methods 1998; 221: 77_85.
65 Yuki Y, Kato K. A 22 kDa human growth hormone specific
enzyme-linked immunosorbent assay. Biol Pharm Bulletin 1994;
17: 977_9.
66 Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres
Best Pract Res Clin Endocrinol Metab 2000; 14: 99_109.
67 Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of
doping with human growth hormone. Lancet 1999; 353: 895.
68 Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, Carlsson
L, Boguszewski CL, et al. Changes in non-22-kilodalton (kDa)
isoforms of growth hormone (GH) after administration of
22-kDa recombinant human GH in trained adult males. J Clin Endocrinol
Metab 2001; 86: 1731_7.
69 Nelson AE, Howe CJ, Nguyen TV, Leung KC, Trout GJ, Seibel
MJ, et al. Influence of demographic factors and sport type on
growth hormone-responsive markers in elite athletes. J Clin
Endocrinol Metab 2006; 91: 4424_32.
70 Erotokritou-Mulligan I, Bassett EE, Kniess A, Sonksen PH, Holt
RI. Validation of the growth hormone (GH)-dependent marker
method of detecting GH abuse in sport through the use of
independent data sets. Growth Horm IGF Res 2007; 17: 416_23.
71 Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca
L, et al. Detection of growth hormone abuse in sport. Growth
Horm IGF Res 2007; 17: 220_6.
72 Fisher JW. Erythropoietin: physiological and pharmacological
aspects. Proc Soc Exp Biol Med 1997; 216: 358_69.
73 Cheung JY, Miller BA. Molecular mechanism of erythropoietin
signaling. Nephron 2001; 87: 215_22.
74 Richmond TD, Chohan M, Barber DL. Turning cells red: signal
transduction mediated by erythropoietin. Trends Cell Biol 2005;
15: 146_55.
75 Delanghe JR, Bollen M, Beullens M. Testing for recombinant
erythropoietin. Am J Hematol 2008; 83: 237_41.
76 Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR,
Cotes PM. Effects of human erythropoietin derived from
recombinant DNA on the anaemia of patients maintained by
chronic haemodialysis. Lancet 1986; 2: 1175_8.
77 Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW.
Correction of the anemia of end-stage renal disease with
recombinant human erythropoietin. Results of a combined phase I and
II clinical trial. N Engl J Med 1987; 316: 73_8.
78 Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa.
Clinical evolution of a pleiotropic cytokine. Arch Intern Med
2004; 164: 262_76.
79 Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC,
et al. Cloning and expression of the human erythropoietin gene. Proc
Natl Acad Sci U S A 1985; 82: 7580_4.
80 Sherwood JB, Carmichael LD, Goldwasser E. The heterogeneity
of circulating human serum erythropoietin. Endocrinology 1988;
122: 1472_7.
81 Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that
human serum erythropoietin differs from recombinant human
erythropoietin. Blood 2001; 98: 3626_34.
82 Weitzhandler M, Kadlecek D, Avdalovic N, Forte JG, Chow D,
Townsend RR. Monosaccharide and oligosaccharide analysis of
proteins transferred to polyvinylidene fluoride membranes after
sodium dodecyl sulphate-polyacrylamide gel electrophoresis. J
Biol Chem 1993; 268: 5121_30.
83 Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Gawlitzek M,
et al. Engineering Chinese hamster ovary cells to maximize sialic acid
content of recombinant glycoproteins. Nat Biotechnol 1999;
17: 1116_21.
84 Spinowitz BS, Pratt RD; Epoetin Delta 2002 Study Group.
Epoetin delta is effective for the management of anaemia
associated with chronic kidney disease. Curr Med Res Opin 2006; 22:
2507_13.
85 Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L,
et al. Enhancement of therapeutic protein
in vivo activities through glycoengineering. Nat Biotechnol 2003; 21: 414_21.
86 Egrie JC, Browne JK. Development and characterization of
novel erythropoiesis stimulating protein (NESP). Br J Cancer
2001; 84: 3_10.
87 Jelkmann W. Novel erythropoietic agents: a threat to
sportsmanship. Medicina Sportiva 2007; 11: 32_42.
88 Eichner ER. Blood doping: infusions, erythropoietin and
artificial blood. Sports Med 2007; 37: 389_91.
89 Lappin TR, Maxwell AP, Johnston PG. EPO's alter ego:
erythropoietin has multiple actions. Stem Cells 2002; 20: 485_92.
90 Locatelli F, Del Vecchio L. Pure red cell aplasia secondary
treatment with erythropoietin. J Nephrol 2003; 16: 461_6.
91 Trial J, Rice L, Alfrey CP. Erythropoietin withdrawal alters
interactions between young red blood cells, splenic endothelial
cells, and macrophages: an in vitro model of neocytolysis. Investig
Med 2001; 49: 335_45.
92 Catlin DH, Breidbach A, Elliott S, Glaspy J. Comparison of the
isoelectric focusing patterns of darbepoetin alfa, recombinant
human erythropoietin, and endogenous erythropoietin from
human urine. Clin Chem 2002; 48: 2057_9.
93 Lasne F, Martin L, Crepin N, de Ceaurriz J. Detection of
isoelectric profiles of erythropoietin in urine: differentiation of natural
and administered recombinant hormones. Anal Biochem 2002;
311: 119_26.
94 Lasne F. Double-blotting: a solution to the problem of
non-specific binding of secondary antibodies in immunoblotting
procedures. J Immunol Methods 2001; 253: 125_31.
95 Gore CJ, Parisotto R, Ashenden MJ, Stray-Gundersen J, Sharpe K,
Hopkins W, et al. Second-generation blood tests to detect
erythropoietin abuse by athletes. Haematologica 2003; 88: 333_44.
96 Parisotto R, Gore CJ, Emslie KR, Ashenden MJ, Brugnara C,
Howe C, et al. A novel method utilising markers of altered
erythropoiesis for the detection of recombinant human
erythropoietin abuse in athletes. Haematologica 2000; 85: 564_72.
97 Parisotto R, Wu M, Ashenden MJ, Emslie KR, Gore CJ, Howe C,
et al. Detection of recombinant human erythropoietin abuse in
athletes utilizing markers of altered erythropoiesis.
Haematologica 2001; 86: 128_37.
98 Connes P, Caillaud C, Simar D, Villard S, Sicart MT, Audran M.
Strengths and weaknesses of established indirect models to detect
recombinant human erythropoietin abuse on blood samples
collected 48-hr post administration. Haematologica 2004; 89: 891_2.
99 Bajla I, Hollander I, Minichmayr M, Gmeiner G, Reichel CH.
GASepo_a software solution for quantitative analysis of digital
images in Epo doping control. Comput Methods Programs
Biomed 2005; 80: 246_70.
100 Lamon S, Robinson N, Sottas PE, Henry H, Kamber M, Mangin
P, et al. Possible origins of undetectable EPO in urine samples.
Clin Chim Acta 2007; 385: 61_6.
101 Chevenne D, Trivin F, Porquet D. Insulin assays and reference
values. Diabetes Metabol 1999; 25: 459_76.
102 Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G,
Gall MA. Insulin analogues (insulin detemir and insulin aspart)
versus traditional human insulins (NPH insulin and regular
human insulin) in basal_bolus therapy for patients with type 1
diabetes. Diabetologia 2004; 47: 622_9.
103 Standl E. Insulin analogues_state of the art. Horm Res 2002; 57:
40_5.
104 Barnett AH, Owens DR. Insulin analogues. Lancet 1997; 349:
47_51.
105 Bowsher RR, Lynch RA, Brown-Augsburger P, Santa PF, Legan
WE, Woodworth JR, et al. Sensitive RIA for the specific
determination of insulin lispro. Clin Chem 1999; 45: 104_10.
106 Andersen L, Jorgernsen PN, Jensen LB, Walsh D. A new insulin
immunoassay specific for the rapid-acting insulin analog, insulin
aspart, suitable for bioavailability, bioequivalence, and
pharmacokinetic studies. Clin Biochem 2000; 33: 627_33.
107 Strauss RH, Yesalis CE. Anabolic steroids in the athlete. Annu
Rev Med 1991; 42: 449_57.
108 Musa MA, Khan MO, Cooperwood JS. Medicinal chemistry and
emerging strategies applied to the development of selective
estrogen receptor modulators (SERMs). Curr Med Chem 2007; 14:
1249_61.
109 Jordan VC. SERMs: meeting the promise of multifunctional
medicines. J Natl Cancer Inst 2007; 99: 350_6.
110 Brodie A, Lu Q, Long B. Aromatase and its inhibitors. J Ster
Biochem Molec Biol 1999; 69: 205_10.
111 Robertson JF. Selective oestrogen receptor modulators/new
antioestrogens: a clinical perspective. Cancer Treat Rev 2004;
30: 695_706.
112 Wingate MB. Recent advances in investigation and treatment of
infertility. Can Med Assoc J 1969; 101: 43_9.
113 Mareck U, Geyer H, Guddat S, Haenelt N, Koch A, Kohler M,
et al. Identification of the aromatase inhibitors anastrozole and exemestane
in human urine using liquid chromatography/tandem mass
spectrometry. Rapid Commun Mass Spectrom 2006; 20: 1954_62.
114 Mazzarino M, Botre F. A fast liquid chromatographic/mass
spectrometric screening method for the simultaneous detection of
synthetic glucocorticoids, some stimulants, anti-oestrogen drugs
and synthetic anabolic steroids. Rapid Commun Mass Spectrom
2006; 20: 3465_76.
115 Poon GK, Chui YC, McCague R, Linning PE, Feng R, Rowlands
MG, et al. Analysis of phase I and phase II metabolites of
tamoxifen in breast cancer patients. Drug Metabol Dispos 1993;
21: 1119_24.
116 Jones RM, Lim CK. Toremifene metabolism in rat, mouse and
human liver microsomes: identification of
alpha-hydroxytoremifene by LC-MS. Biomed Chrom 2002; 16: 361_3.
117 Mareck U, Sigmund G, Opfermann G, Geyer H, Schänzer W.
Identification of the aromatase inhibitor aminoglutethimide in
urine by gas chromatography/mass spectrometry. Rapid Commun
Mass Spectrom 2002; 16: 2209_14
118 Mareck U, Sigmund G, Opfermann G, Geyer H, Thevis M,
Schänzer W. Identification of the aromatase inhibitor letrozole
in urine by gas chromatography/mass spectrometry. Rapid
Commun Mass Spectrom 2005; 19: 3689_93.
119 GTx website: http://www.gtxinc.com/
120 Walsh FS, Celeste AJ. Myostatin: a modulator of skeletal-muscle
stem cells. Biochem Soc Trans 2005; 33: 1513_7.
121 Solomon AM, Bouloux PM. Modifying muscle mass_the
endocrine perspective. J Endocrin 2006; 191: 349_60.
122 Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal
transduction pathway through activin receptors as a therapeutic
target of musculoskeletal diseases and cancer. Endocrin J 2007;
55: 11_21.
123 Grobert L, Martin LJ, Poncelet D, Pirottin D, Brouwers B, Riquet
J, et al. A deletion in the bovine myostatin gene causes the
double-muscled phenotype in cattle. Nat Genet 1997; 17: 71_4.
124 Schuelke M, Wagner KR, Stolz LE, Hübner C, Riebel T, Kömen
W, et al. Myostatin mutation associated with gross muscle
hypertrophy in a child. N Engl J Med 2004; 350: 2682_8.
125 McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle
mass in mice by a new TGF-beta superfamily member. Nature
1997; 387: 83_90.
126 McPherron AC, Lee SJ. Suppression of body fat accumulation in
myostatin-deficient mice. J Clin Invest 2002; 109: 595_601.
127 Lee SJ, McPherron AC. Regulation of myostatin activity and
muscle growth. Proc Natl Acad Sci USA 2001; 98: 9306_11.
128 Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore
LA, Ahima RS, et al. Functional improvement of dystrophic
muscle by myostatin blockade. Nature 2002; 420: 418_21.
129 Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana
TS. Myostatin propeptide-mediated amelioration of dystrophic
pathophysiology. FASEB J 2005; 19: 543_9.
130 Lee SJ, Reed LA, Davies MV, Girgenrath S, Goad ME, Tomkinson
KN, et al. Regulation of muscle growth by multiple ligands
signaling through activin type II receptors. Proc Natl Acad Sci USA
2005; 102: 18117_22.
|